Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Weight-Loss Drug One-Year Data Enough For Safety and Efficacy – Cmte.

Executive Summary

One-year trial data for weight-control drugs provides enough information to establish efficacy and safety for approval, a majority of FDA's Endocrinologic & Metabolic Drugs Advisory Committee concluded Sept. 8

You may also be interested in...



FDA Says No To Metabolic Syndrome; New Obesity Guidance Takes Hard Line

FDA currently views metabolic syndrome as "not necessarily" a distinct disease entity, according to the agency's draft guidance on obesity products

FDA Says No To Metabolic Syndrome; New Obesity Guidance Takes Hard Line

FDA currently views metabolic syndrome as "not necessarily" a distinct disease entity, according to the agency's draft guidance on obesity products

Sanofi-Aventis Expects Broad Label For Acomplia After FDA Obesity Panel

Sanofi-Aventis is interpreting the results of FDA's recent Endocrinologic & Metabolic Drugs Advisory committee on obesity drug development as a sign that its obesity/smoking cessation agent Acomplia will be approved with a broad label

Related Content

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel